News
Newer antihyperglycemic drugs have distinctive CV, kidney benefits
March 12, 2019
SGLT2 inhibitors and GLP-1 RAs have different effects on cardiovascular and kidney disease outcomes in patients with type 2 diabetes.
![1]()
News
ICU admissions raise chronic condition risk
February 27, 2019
Compared to non-ICU visitors, patients had greater risk of developing new chronic conditions after discharge.
![1]()
News
SGLT2 inhibitors morph into HF drugs
February 7, 2019
“We’re increasingly moving to an age where these agents are actually cardiovascular drugs that happen to lower blood glucose.” – Dr. Akshay S. Desai
![1]()
News
Intensive insulin added no benefit for hyperglycemia after ischemic stroke
February 7, 2019
Results from a large RCT showed intensive and standard insulin regimens produced similar clinical outcomes after an acute ischemic stroke.
![1]()
News
Metformin associated with acidosis only in patients with eGFR 30 mL/min per 1.73 m 2
January 17, 2019
Does metformin increase the risk of lactic acidosis in chronic kidney disease (CKD)?
![1]()
News
SGLT-2 inhibitors promising for heart failure prevention, not treatment
January 12, 2019
LOS ANGELES – The combination of heart failure and diabetes is particularly lethal.
![1]()
News
New diabetes drugs solidify their cardiovascular and renal benefits
January 7, 2019
CHICAGO – Empagliflozin’s heart failure and renal benefits surprised when reported in 2015. The evidence has grown stronger and broader since.
![1]()
News
Nasal glucagon ‘viable alternative’ to intramuscular administration
November 20, 2018
BERLIN – Severe hypoglycemia was reversed successfully in all patients with type 1 diabetes mellitus given nasal glucagon.
![1]()
Opinion
Transforming glycemic control at Norwalk Hospital
November 20, 2018
Norwalk Hospital created a Glycemic Care Team to focus on improving the quality of care for inpatients with diabetes.
![1]()
News
Lower glucose targets show improved mortality in cardiac patients
November 9, 2018
Lower blood glucose targets in critically ill cardiac patients are associated with lower 30-day mortality, compared with higher targets.
